CBB-201 is a monoclonal antibody targeting IL-4Rα.

A Phase 2b trial of CBP-201 (WW001) met its primary endpoint and key secondary endpoints in the treatment of moderate-to-severe AD (see Ströber et al, Maui Derm 2022).

Serum thymus- and activation-regulated chemokine (TARC) has an important role in allergic diseases such as atopic dermatitis. CCL17 (TARC) is a CC chemokine encoded by the CC17 gene. A human TARC antagonist and a human monoclonal antibody against TARC (CBP-201) are currently in clinical trials for the treatment of AD.

CBP-201 is a human monoclonal antibody that targets IL-4Rα. CBP-201 has been shown to reduce TARC, IgE and IL-4 levels in vitro and in vivo.

Table 1: Disease characteristics at baseline by high and low TARC level in this Phase 2b trial

<table>
<thead>
<tr>
<th>TARC Level</th>
<th>Eczema Area and Severity Index (EASI)</th>
<th>Investigator’s Global Assessment (IGA)</th>
<th>Serum TARC level (pg/mL)</th>
<th>Serum IgE level (IU/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>Median 10.9 (IQR: 6.1–15.7)</td>
<td>Median 0 (IQR: 0–1)</td>
<td>Median 75 (IQR: 38–117)</td>
<td>Median 25 (IQR: 15–40)</td>
</tr>
</tbody>
</table>

Efficacy by baseline TARC

In another post hoc analysis, patients with higher baseline EASI score tended to experience a greater treatment effect in terms of % change in EASI score from baseline (Figure 2).

Efficacy by baseline EASI

A post hoc analysis of biomarkers showed that serum TARC level at Week 16 was not correlated with % change in EASI score or % change in IGA score, as measured in the global trial population (Strober et al, Maui Derm 2022).

Safety by baseline TARC

No new safety signals were noted and adverse events were balanced across all groups. AEs were similar to placebo (See Strober et al, Maui Derm 2022).

References:


Footnotes:

* Extreme values for TARC or IgE were imputed with 0 (lowest) or largest values of TARC or IgE assays.

Abbreviations:

AD, atopic dermatitis; BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; IQR, interquartile range; NS, not significant; Q2W, every 2 weeks; Q4W, every 4 weeks; IGA, Investigator’s Global Assessment.

Abbreviations:

AD, atopic dermatitis; BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; IQR, interquartile range; NS, not significant; Q2W, every 2 weeks; Q4W, every 4 weeks; IGA, Investigator’s Global Assessment.